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Renal transplantation has gradually become commonplace since the 
first successful attempt in the 1950s, and is the preferred mode of 
renal replacement therapy for many patients with end-stage renal 
disease. The widespread use of this treatment modality is largely due 
to improvement in short-term outcome from ~50% in the first year 
for the earliest attempts to >90% in the first year in many centres 
around the world today.[1,2] Much of this improvement is due to the 
introduction of new and more effective immunosuppressive agents 
since the 1980s, when cyclosporine was first used, as well as improved 
surgical techniques.[2,3] However, together with the achievement 
of better immunosuppression came issues and consequences 
associated with such therapy, including infection, drug toxicity and 
metabolic complications such as new-onset diabetes. These also 
profoundly affect outcome. It is therefore evident that to achieve 
further improvements in the outcome of renal transplantation, it is 
necessary not only to prevent graft rejection by achieving effective 
immunosuppression but also to identify and if possible prevent or 
effectively manage the consequences of such therapy.
The occurrence of clinical hyperglycaemia in the post-transplant 
period has been recognised from the early days of renal transplantation. 
It was initially described as steroid diabetes, because steroids were 
the mainstay of transplant immunosuppression and have long been 
recognised as a cause of both transient hyperglycaemia and established 
diabetes mellitus in the general population. With the arrival of 
cyclosporine and newer immunosuppressive medications, as well as 
the increasingly widespread practice of transplantation, it soon became 
evident that diabetes in the post-transplant period was multi factorial, 
and new terms such as ‘post-transplant diabetes mellitus’ and ‘new-
onset diabetes after transplant’ (NODAT) were developed.
Objectives
To investigate the incidence of and clinical and genetic risk factors 
that may predispose to the occurrence of NODAT in renal allograft 
recipients at Groote Schuur Hospital, Cape Town, South Africa (SA).
Methods
We performed a retrospective cohort folder review of all patients 
who received a renal transplant and follow-up at our centre from 
1 January 2004 to 31 December 2008, and were at least 18 years 
old at the time of the study. Patients were excluded if they had 
primary non-function of the allograft or were diabetic before the 
transplant. Information retrieved from the folders was recorded on 
a data collection sheet for further analysis. Data obtained included 
demographic details, body weight at transplant, type of underlying 
renal disease, duration and type of dialysis received, date of and 
age at transplant, number of previous transplants, family history of 
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Background. The outcome of renal transplantation depends on achieving effective immunosuppression while minimising the consequences 
of such treatment. The occurrence of new-onset diabetes in the post-transplant period has been associated with several risk factors including 
some immunosuppressive medication. Better understanding of the clinical and genetic risk factors associated with new-onset diabetes after 
transplant (NODAT) could enable risk stratification of patients in the pre-transplant period, with the goal of applying measures that will 
reduce the incidence.
Objectives. To ascertain the incidence of and clinical and genetic risk factors that predispose to NODAT, and to examine its effect on the 
outcome of renal transplantation.
Methods. We performed a retrospective cohort review of all renal transplants at Groote Schuur Hospital, Cape Town, South Africa, between 
2004 and 2008. Patients who were lost to follow-up or had pre-transplant diabetes or primary non-function were excluded. A subset of the 
cohort who gave informed consent was enlisted for genetic tests.
Results. We identified 111 patients who met the inclusion criteria. The incidence of NODAT was 18.0% (n=20 patients). Risk factors for 
NODAT included age at transplant (p=0.03), body weight (p=0.04), treatment for acute cellular rejection (p=0.02) and polycystic kidney 
disease as the cause of renal failure (p=0.005). None of the genes investigated (TCF7L2 rs11196205, rs12255372 and rs7903146 and HNF1β 
rs1800575, rs121918671 and rs121918672) was found to be significantly associated with the risk of NODAT. The genotype frequencies for 
the single-nucleotide polymorphisms studied were closer (although not identical) to those reported for Caucasians than to those reported 
for the Yoruba (black) population in West Africa. Overall patient survival was 78% at five years, while graft survival was 72%. There was no 
significant difference in patient or graft survival between the group with NODAT and the group without.
Conclusions. NODAT was common in renal transplant recipients. Some risk factors predate transplant and could be used to risk-stratify 
patients to determine appropriate risk-reduction strategies. The genetic determinants for NODAT in this population may differ from those 
reported elsewhere. NODAT had no impact on patient or graft survival in this cohort.
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diabetes, and immunosuppressive protocol used. Laboratory data 
obtained included fasting plasma glucose, serum creatinine and 
total cholesterol before the transplant as well as serially after the 
transplant at 3, 6 and 12 months and then annually thereafter until 
the patient reached an endpoint (return to dialysis or death) or was 
lost to follow-up, or until the end of the study period. The onset of 
diabetes was determined from the laboratory data (fasting plasma 
glucose (FPG) >7 mmol/L or random plasma glucose >11.1 mmol/L) 
and clinical features.
Genetic study
Patients were enlisted for genetic tests if they gave written informed 
consent. The study was approved by the Groote Schuur Hospital/
University of Cape Town Research Ethics Committee in accordance 
with the Helsinki Declaration (ref. no. REC/REF 149/2009).
DNA isolation
Isolation of DNA from whole-blood samples was done using the 
‘salting out’ method as described by Mullis and Faloona,[4] with minor 
modifications. Specifically, the red blood cells were first separated out 
from the white blood cells (WBCs) that contain the DNA. The WBC 
membranes were then lysed with a protein denaturant (Proteinase K; 
Thermo Scientific, USA) and detergent (sodium dodecyl sulphate) to 
release the DNA from the nucleus. The protein content of the cell was 
precipitated out, separated from the DNA and discarded. The DNA 
was then precipitated using 100% ethanol, washed and reconstituted. 
The DNA pellet was reconstituted by adding 100 µL of DNA rehy-
dration solution. DNA stock solutions were stored at –20˚C.
DNA quality and integrity 
The quality of the DNA samples obtained was assessed using 
various techniques, including spectrophotometry (to measure the 
DNA concentration and purity of the samples) using the Nanodrop 
1000 spectrophotometer (Thermo Scientific, USA) and agarose gel 
electrophoresis (to determine the integrity of the DNA samples) 
using a 1% (w/v) agarose gel (Lonza, Switzerland) with a final 
concentration of 0.5 µg/ml. Ethidium bromide (Sigma, USA) DNA 
stain was incorporated into the gel, and electrophoresis was perfomed 
at 140 V for 30 - 40 minutes. The DNA was visualised under ultra-
violet light using the UVIPRO transilluminator (UVItec, UK).
Gene annotation, primer design and polymerase chain  
reaction (PCR)
Bioinformatic tools were used to annotate the genes of interest 
(TCF7L2-  NG_012631.1 and HNF1β- NG_013019.1) with DNA 
variation features and aid experimental primer/assay design. The 
DNA sequences for TCF7L2 and HNF1β were taken from the genome 
browsers, National Centre for Biotechnology Information (NCBI), 
version 36 (http://www.ncbi.nlm.nih.gov), and Ensemble, version 54 
(http://www.ensemble.org/index.html).
PCR techniques were used to amplify patients’ DNA and to identify 
their genotypes for the various single-nucleotide polymorphisms 
(SNPs) studied.
Statistical analysis
The data were analysed using the SPSS statistical package, version 
18.1 (IBM, USA) and R statistics.[5] Continuous data were expressed 
as means, while discrete data were expressed as frequencies and 
percentages. The χ2 test and logistic regression model were used to 
test for statistical significance, and p<0.05 was chosen as the level 
of statistical significance. For the Kaplan-Meier survival curves, 
the initiation date was the date of transplant, and graft and patient 
survival was censored for loss to follow-up, completion of the study 
or outcome, i.e. return to dialysis or death with a functioning graft.
Results
Several clinical characteristics of the study population were analysed 
to determine whether they were associated with an increased risk of 
NODAT in this cohort. A higher age and weight at transplant, treatment 
for acute cellular rejection and polycystic kidney disease were found 
to be significantly associated with the risk of NODAT. Laboratory 
data such as serum cholesterol, serum creatinine at discharge and 
urine protein/creatinine ratio, as well as systolic and diastolic blood 
pressure, were similar in those with and without NODAT. Mean FPG 
at discharge was significantly higher in the group with NODAT. Other 
clinical parameters investigated were not associated with the risk of 
NODAT in this retrospective cohort (Table 1).
The proportion of subjects who developed NODAT and the time 
from the date of the transplant to the diagnosis of NODAT were 
analysed using a Kaplan-Meier curve. There was an incidence of 
18.0% (20/111). Most cases of NODAT were diagnosed within the 
first 6 months after the transplant (Fig. 1).
The incidence of NODAT was assessed separately in the 
two main treatment arms (cyclosporine- v. tacrolimus-based 
immunosuppression) to determine whether either of the two drugs 
posed a greater risk of NODAT. Although the group treated with 
tacrolimus had slightly more cases of NODAT (5/25, 20.0%) than the 
group treated with cyclosporine (15/86, 17.4%), this difference was 
not statistically significant (Fig. 2).
Table 1. Clinical characteristics of the study population and 
the risk of NODAT
Features No NODAT NODAT p-value
Age at transplant (yr), mean 37 44 0.03*
Weight at discharge (kg), mean 67 74 0.04*
Sex, n (%)
Female 34 (77.3) 10 (22.7) 0.2
Male 57 (85.1) 10 (14.9) 0.2
Race, n (%)
Mixed 55 (78.6) 15 (21.4) 0.06
Black 24 (88.9) 3 (11.1) 0.06
White 12 (85.7) 2 (14.3) 0.06
Family history of DM, n (%) 62 (93.9) 4 (6.1) 0.3
SBP (mmHg), mean 133 135 0.7
DBP (mmHg), mean 81 79 0.5
FBG at discharge (mmol/L), 
mean
5.8 8.1 0.02*
Cholesterol (mmol/L), mean 5.3 5.1 0.6
UPCR, mean 0.05 0.05 0.8
Creatinine at discharge 
(µmol/L), mean
190 223 0.6
Donor type (CD), n (%) 61 (79.2) 16 (20.8) 0.8
Tacrolimus use, n (%) 18 (78.3) 5 (2.7) 0.1
Treatment for ACR, n (%) 5 (45.5) 6 (54.5) 0.02*
Polycystic kidneys, n (%) 3 (27.3) 8 (72.7) 0.005*
Dialysis type (PD), n (%) 29 (93.5) 2 (6.5) 0.7
Dialysis duration (d), mean 832 689 0.5
NODAT = new-onset diabetes after transplant; DM = diabetes mellitus; SBP = systolic 
blood pressure; DBP = diastolic blood pressure; FBG = fasting blood glucose; UPCR = 
urine protein/creatinine ratio; CD = cadaver donor; ACR = acute cellular rejection; PD = 
peritoneal dialysis.
*Statistically significant risk factors (p<0.05).
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The time from date of transplant to diagnosis of NODAT was assessed 
separately in the two treatment arms (tacrolimus v. cyclosporine). 
Although the risk for NODAT was highest in the first 6 months for 
both treatment arms, all cases of NODAT in the tacrolimus treatment 
arm had occurred by 12 months, while the risk continued until 36 
months for those treated with cyclosporine.
The impact of NODAT on graft survival was analysed using a 
Kaplan-Meier plot. Graft survival at 5 years was 72% (Fig. 3). There 
was no significant difference in graft survival between the patients 
with NODAT and those without (p=0.4).
Patient survival over the study period was analysed using a 
Kaplan-Meier plot. The 5-year patient survival in this cohort was 78% 
(Fig. 4). There was no significant difference in survival between the 
group with NODAT and the group without (p=0.42).
In summary, the genotyping results (Table 2) showed no 
significant differences between the case and control groups when 
the frequencies of the SNPs selected for the study were compared. 
Logistic regression analysis was used to test for statistical significance. 
For comparison with published genotyping frequencies in other 
population groups, data were obtained from the NCBI database 
(http://www.ncbi.nlm.nih.gov). The genotype frequencies for the 
TCF7L2 SNPs rs12255372, rs11196205 and rs7903146 in this SA 
population followed a distribution closer to that observed in the 
European Caucasian population than to that in the Yoruba (Nigerian) 
population. Genotyping frequencies for the SNPs in HNF1β were not 
available on the public databases for comparison.
Discussion
The incidence of NODAT in this study was 18.0% (Fig. 1). This 
is similar to the findings in another study, which used similar 
definitions for NODAT.[6,7] Harrichund et al.[8] reported a similar 
prevalence of 15.6% in Johannesburg. The age distribution of our 
patient cohort reflects a relatively young population, owing to the 
systematic exclusion of patients aged >60 years from the transplant 
programme in the public sector. Although the risk of NODAT 
continued throughout the duration of follow-up, most of the incident 
cases occurred within the first 6 months after the transplant (Fig. 1). 
This is similar to findings in several other studies,[7,9] and supports the 
probability that transplant-related factors such as immunosuppressive 
medications, viral infections and the stress of surgery are major 
contributors to the risk of diabetes in the post-transplant period. 
The first few months after a transplant, when the risk of acute 
rejection is high, are characterised by high levels of exposure to 
immunosuppressive drugs. Extra doses of steroids increase the risk 
of viral and other opportunistic infections, making this a period of 
considerable vulnerability for renal transplant recipients.
The risk factors associated with NODAT in this study included 
age at transplant (>40 years), higher weight at transplant, treatment 
for acute cellular rejection, and polycystic kidney disease (Table 1). 
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Fig. 1. Kaplan-Meier curve showing the incidence of NODAT over time. 
The blue circles represent patients who developed NODAT. (NODAT = new-
onset diabetes after transplant.)
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Fig. 2. Incidence of NODAT according to treatment arm (A = cyclosporine; 
B = tacrolimus). (NODAT = new-onset diabetes after transplant.)
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Fig. 3. Kaplan-Meier curve showing graft survival over time. The blue line 
represents survival function, while the blue circles represent an event (death, 
return to dialysis or re-transplant).
Fig. 4. Kaplan-Meier curve showing patient survival over time. The blue line 
represents survival function, while the blue circles represent an event (death).
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These findings are in keeping with those 
of other studies reporting that older age at 
transplant is significantly associated with 
an increased risk of NODAT.[7,10] We know 
that the pathophysiology of post-transplant 
diabetes mimics that of type 2 diabetes 
mellitus in the general population. It is 
therefore not unexpected that they should 
follow similar epidemiological patterns in 
terms of age.
We found an increased risk of NODAT 
to be significantly associated with higher 
body weight at the time of discharge after 
the transplant (Table 1). Conflicting findings 
on the relationship between body mass 
and NODAT have been reported. A high 
body mass index (BMI)/body weight was 
associated with an increased risk of NODAT 
in several studies,[6,9,10] while others found 
no significant association. This may reflect 
the different indices of body mass used in 
the studies, such as BMI v. weight, as well 
as the timing of measurement, e.g. before 
or immediately after the transplant or at the 
time of discharge, as the presence of fluid 
overload may have a considerable effect on 
weight at the different times. Furthermore, 
the number of overweight patients may be 
under-represented in some cohorts. We used 
weight at the time of discharge in our study, 
as this may be more representative of the 
dry weight in patients with a functioning 
graft than pre-transplant or immediate post-
transplant weight.
Treatment for acute cellular rejection 
was found to be significantly associated 
with an increased risk of NODAT in this 
study (Table 1). Treatment for acute cellular 
rejection reflects an increase in the total 
dose of steroids used in these individuals, 
as all patients in the cohort received similar 
doses of oral steroids except for those with 
acute cellular rejection, who were all given 
extra pulses of high-dose methylprednisone. 
Several other studies have reported similar 
findings, showing that the risk of NODAT is 
directly related to the use of steroids.[11,12] This 
association is in agreement with established 
knowledge on the diabetogenic potential of 
steroids in the general population. However, 
we did not find a significant difference 
between cyclosporine and tacrolimus in 
terms of their contribution to the risk of 
NODAT (Table 1). Although there was a 
trend toward a higher rate of NODAT in 
the group treated with tacrolimus, it was 
not statistically significant (Fig. 2). This is 
similar to findings in some other studies, a 
few of which had similar methodology to 
ours.[6,13] Several further studies, however, 
report a significantly greater role for 
tacrolimus in the causation of NODAT.[9,12] 
Our finding may reflect the relatively small 
number of patients who received tacrolimus 
compared with cyclosporine in our cohort. 
It is also difficult to accurately tease out the 
contribution of each of the immusuppressive 
medications to the risk of NODAT; instead, 
the overall level of immunosuppression may 
be a simpler indicator of risk.
Polycystic kidneys as a cause of renal 
failure were also found to be significantly 
associated with an increased risk of NODAT 
in our cohort (Table 1), and several other 
studies have reported similar findings. [14- 16] 
Whether this association is due to an 
increased risk of maturity-onset diabetes of 
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the young (MODY) type 5 (also known as ‘renal cyst and diabetes’ 
syndrome) in this group of patients is worth exploring. Mutations in 
the HNF1β gene, which is known to cause MODY type 5, have also 
been shown to contribute to type 2 diabetes in some populations.[17-19]
A family history of diabetes was not significantly associated with 
an increased risk of NODAT, and nor were gender or race (Table 1). 
Although there was a trend to an increased risk in patients of mixed 
ancestry, this did not achieve statistical significance. The lack of a 
significant association between race and NODAT in this study may 
be due to the disproportionately high representation of people of 
mixed ancestry in this cohort compared with other racial groups.
Other clinical and biochemical characteristics such as type of donor 
(cadaver or live), blood pressure, serum cholesterol and urine protein/
creatinine ratios were similar in the NODAT and control groups.
We also investigated some possible genetic risk factors for NODAT. 
None of the three SNPs on the TCF7L2 gene investigated (rs11196205, 
rs12255372 and rs7903146) was found to be significantly associated 
with the risk of NODAT (Table 2). A study among Hispanics did not 
find a significant association of polymorphisms in rs7903146 and 
rs12255372 with an increased risk of NODAT.[20] Several studies, 
however, report a significant association between various SNPs on 
the TCF7L2 gene and the risk of NODAT. In Korea, a significant 
association between the risk of NODAT and polymorphisms in the 
TCF7L2 (rs7903146) gene has been reported.[21,22] Another study 
reported a significant association between polymorphisms in the 
TCF7L2 rs7903146 gene only with late-onset post-transplant diabetes 
(later than 2 weeks) and in patients treated with tacrolimus.[23] This 
may imply that the presence of a risk genotype in itself may not be 
sufficient to produce a clinical phenotype but requires the coexistence 
of other environmental determinants such as type and dose of 
immunosuppression. In our study, the fact that tacrolimus was used 
sparingly and only for specific indications may explain the lack of 
significant association between this gene and NODAT. Among the 
Zulu (black) people of KwaZulu-Natal, SA, a significant relationship 
was found between polymorphisms on the rs7903146 SNP on the 
TCF7L2 gene and diabetes in the general population.[24] Similar work 
has yet to be performed among other racial groups in SA. The lack 
of a significant association between NODAT and the TCF7L2 gene in 
our study may also be explained by the fact that most of our cohort 
consisted of people of mixed ancestry. Furthermore, the number of 
SNPs studied was few, and it may be that the risk-carrying SNPs in 
this population are different from those we studied. The genotype 
frequencies in our cohort for the SNPs studied were closer (although 
not identical) to those reported for the European population and 
differed from those reported for the Yoruba population in West 
Africa. This again highlights the uniqueness of our cohort in terms 
of race, being neither purely black nor Caucasian.
Three SNPs in the HNF1β gene (rs121918671, rs121918672 and 
rs1800575) were examined. Rs121918672 was homozygous in the 
entire cohort and could not be analysed further (Table 2). For 
rs1800575, only one individual was heterozygous for the risk allele, 
and this also could not be investigated further (Table 2). For 
rs121918671, we found no significant relationship between carrying 
the risk allele and NODAT (Table 2). This may also be explained 
by population differences with regard to the disease-carrying SNPs 
on specific genes. This study has not been performed previously 
in our population. It may therefore imply that results from other 
populations with different characteristics from ours cannot be 
directly applied to our population.
We found no significant difference in graft (Fig. 3) or patient 
(Fig. 4) survival between the group with NODAT and the controls. 
This differs from what has been reported in several other studies, 
and may be due to the relatively short duration of follow-up. Some 
studies have also reported no difference in outcome between subjects 
with NODAT and those without, especially in the short term.[25,26] The 
mean serum creatinine level and glomerular filtration rate were also 
similar in the two groups (Table 1).
Recommendations
Insulin resistance has been identified as the mechanism by which 
weight gain increases the risk of type 2 diabetes in the general 
population. Could the mechanism in NODAT be the same? Do all 
the risk factors identified increase the incidence of NODAT via the 
same pathophysiological mechanism? Further studies need to be 
conducted to answer these questions. Despite a negative outcome 
on the study of genetic influence on NODAT, we nevertheless 
recommend an in-depth study of this factor with a larger sample size 
and a less skewed population.
Conclusions
NODAT is a common complication of renal transplantation. Some 
of the risk factors predate transplant and could be used to risk-
stratify patients and apply risk-reduction strategies such as lifestyle 
modification and use of less diabetogenic immunosuppressive 
protocols. Genotype frequencies for the SNPs studied differ from 
those reported for other populations, underscoring the genetic 
heterogeneity of our study population.
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